SCHEMBL1033829

SCHEMBL1033829

OCc1ccc(OC(F)F)c(OCc2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 4/20 0.46
PDE4B Q07343 3/20 0.46
PDE4C Q08493 3/20 0.46
PDE4D Q08499 3/20 0.46
SLC2A1 P11166 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
HPGD P15428 1/20 0.45
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
XBP1 P17861 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
TSHR P16473 1/20 0.43
FOLH1 Q04609 1/20 0.43
TTR P02766 1/20 0.42
BCHE P06276 1/20 0.41
PTGER1 P34995 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL584781 0.86 SLC2A1 (0.56) SLC2A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL30280404 0.86 SLC2A1 (0.56) SLC2A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL1027720 0.85 PDE4B (0.43) PDE4APDE4BPDE4CPDE4DSLC2A1
SCHEMBL20064613 0.85 MAPK1 (0.46) PDE4APDE4BPDE4CPDE4DSLC2A1
SCHEMBL7418541 0.82 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DNPC1
SCHEMBL20063944 0.82 FFAR1 (0.46) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL1030549 0.82 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DSLC2A1
SCHEMBL10934702 0.81 MAPT (0.53) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL23981776 0.81 PDE4B (0.44) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL20064612 0.81 SLC6A4 (0.56) SMN1; SMN2NPC1RAB9AHTTMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113121417-A Novel piperidine derivative and pharmaceutical application thereof 苏州盛迪亚生物医药有限公司 2021-07-16 CN disclosed
EP-1481969-B1 PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2011-01-19 EP disclosed
EP-1481969-B1 PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2011-01-19 EP disclosed
US-7425567-B2 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-16 US disclosed
US-7425567-B2 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-16 US disclosed
US-7425567-B2 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-09-16 US disclosed
US-20050080107-A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-04-14 US disclosed
EP-1481969-A1 PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080107-A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient PDCD4, PDE4B, IRAK4 PDE4A 7/4885PDE4B 2/4885PDE4C 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.